WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals
World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

ISSN 2457-0400

Impact Factor  :  5.464

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • WJAHR New Impact Factor

    Its our Pleasure to Inform you that WJAHR Impact Factor has been increased from  4.897 to 5.464 due to high quality Publication at International Level

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR December 2022 Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

  • WJAHR: DECEMBER ISSUE PUBLISHED

    DECEMBER 2022 Issue has been successfully launched on 1 December 2022.

Best Paper Awards

World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.

Best Article of current issue

Download Article : Click here

Indexing

Abstract

EFFECT OF (HYOSCINE BUTYLBROMIDE) ON THE DURATION OF THE FIRST STAGE OF ACTIVE LABOR IN FULL TERM PREGNANT WOMEN

*Alagha Alaa, Mohammad Basel and Issam Aldali

ABSTRACT

Background: Prolonged labor contributes to increased perinatal and maternal morbidity. Active management of labor reduces the number of cesarean deliveries, the number of prolonged labor, and the duration of labor without having any adverse effects on the mother and the fetus. Objective: The aim of this study was to determine the effect of HBB on the duration of the first stage of active labor in full term pregnant women. Methods: The study was a Randomized Control Trail carried out at Tishreen University Hospital in Lattakia-Syria during the period between(2021-2022). study included 143pregnant women in full term with spontaneous onset of labor. The patients were divided into two groups, study group: 73 pregnant women, They received (20mg of hyoscine butylbromide diluted in 9 ml of saline solution) slowly intravenously. Placebo Group: 70 pregnant patients, received placebo(10 mls of intravenous normal saline). The mean duration of the first stage of active labor was compared between the two groups. Results: The observed mean duration of the first stage of labor was significantly shorter (P = 0.002) in the Hyoscine butyl-bromide group (4.36±2.4 h) than in the Placebo group (5.49±2.8 h). There was no significant difference between the two groups in the mean duration of the second and third stages of labor (28.9±10.8 vs. 32.1±11.3 min, p=0,3. And 6.2±2.03 vs. 6.7±3.2 min, p=0,4, respectively). The median APGAR scores at the 1st and 5th minutes were also comparable (8.4±0.9 vs. 8.6±1.1, p=0.1. And 9.3±0.4 vs. 9.5± 0,3, p=0.2, respectively). the side effects of HBB were seen in the two groups, but difference between the both groups was not statistically significant (p value> 0.05). Conclusion: HBB reduced the duration of first stage of labor in pregnant women without adverse maternal and neonatal complications. It is recommended that HBB to be given to women in active phase of labor to reduce the incidence of prolonged labor.

[Full Text Article]